

### ASMS 2017 MP 455

Takanari Hattori<sup>1, 2</sup>, Shuichi Kawana<sup>1</sup>, Yoshihiro Hayakawa<sup>1</sup>, Eiichiro Fukusaki<sup>3</sup>, Mitsuharu Matsumoto<sup>4</sup> 1 Shimadzu Corporation, Kyoto, Japan.

PO-CON1719E

2 Osaka University Shimadzu Analytical Innovation

Research Laboratory, Osaka, Japan.

3 Osaka University, Osaka, Japan.

4 Kyodo Milk Industry Co. Ltd., Tokyo, Japan

# Introduction

The intestinal microbiome plays an important role in health and/or disease because it influences pathological and normal homeostatic functions. Low-molecular-weight metabolites produced by intestinal microbiome are absorbed constantly from the intestinal lumen and carried to systemic circulation; they play a direct role in health and/or disease. There are limited reports concerning the function of metabolites produced by intestinal microbiome. Furthermore, these studies are targeting specific metabolites such as short chain fatty acids but not global metabolites (metabolome). For clarifying the relationship between health and/or disease and metabolome produced by intestinal bacteria, only free bacterial metabolites in the intestinal luminal content (or feces) should be analyzed. In this study, metabolites in feces of young and old mice were analyzed by LC-MS/MS.

## Methods and Materials

### Sample Preparation

Mice feces were diluted with phosphate-buffered saline and extracted by intense mixing. The upper portion was centrifuged and the supernatant was centrifugally filtered. Figure 1 shows the detailed procedures.




Figure 1 Process flow of sample preparation

#### 

#### Mice fecal metabolomics by LC-MS/MS: Comparison between young mice and old mice

### Experimental

Two LC-MS/MS methods (ion-pairing and non-ion-pairing method) were used for analysis. Nexera X2 system coupled with a LCMS-8040 or a LCMS-8050 (Shimadzu Corporation, Japan) was used. In ion-pairing method, separation was achieved on Mastro C18 column (Shimadzu GLC Ltd., Japan). The mobile phase consisted of 15 mM acetic acid and 10 mM tributylamine in water

(A) and methanol (B) under gradient elution. In non-ion-pairing method, separation was achieved on Discovery HS F5-3 column (Sigma-Aldrich, U.S.A.). The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) under gradient elution.

Analytical Condition (Ion-pairing method)

UHPLC (Nexer	a X2 system)
Column	: Mastro C18 (150 mmL.×2.0 mml.D., 2.0 µm)
Mobile phase A	: 15 mM Acetate, 10 mM Tributylaimne/water
В	: Methanol
Flow rate	: 0.3 mL/min
Injection vol.	: 3 µL
Column temp.	: 40°C
MS (LCMS-804	0)
Ionization	: Negative, MRM mode
DL temp.	: 250°C
HB temp	: 400°C
Drying gas	: 10 L/min
Nebulizing gas	: 2.0 L/min

tical Condition (Non-ion-pairing method)	Analytical	
	Analytical	

UHPLC (Nexera X	2 system)
Column : I	Discovery HS F5 (150 mmL.×2.1 mml.D., 3.0 μm)
Mobile phase A : (	0.1% Formate/water
B : (	0.1% Formate/acetonitrile
Flow rate : (	0.25 mL/min
Injection vol. : 3	3 μL
Column temp. : 4	40°C
MS (LCMS-8050)	
Ionization : I	Positive/Negative, MRM mode
DL temp. : 2	250°C

	DL temp.	:	250°C
	HB temp.	:	400°C
	Interface temp.	:	400°C
	Nebulizing gas	:	2.0 L/min
	Drying gas	:	10 L/min
	Heating gas	:	10 L/min
_			





# Result

### Analysis of Metabolites in Mice Fecal by LC-MS/MS

We evaluated 55 and 97 of metabolites in ion-pairing method and non-ion-pairing method respectively. In ion-pairing method, 17 of metabolites were detected in the extract of mice feces (peak area RSD <20%). Main compounds of 17 metabolites were amino acids. In non-ion-pairing method, 75 of metabolites were detected in the 10-fold diluted extract of mice feces

(peak area RSD <20%). Main compounds of 75 metabolites were amino acids and nucleic acid-related substances. Figure 2 shows the MRM chromatogram of extract of mice feces obtained using LC-MS/MS. The list of detected compounds and their repeatability is shown in Table 1.




Figure 2 MRM chromatograms of extract of mice feces

Category	Compounds	Repeatability (%RSD, n=6) R.T. Peak area	
5 ,			
	4-Hydroxyproline	0.11	3.8
	Alanine	0.10	3.0
		0.06	3.0
	Arginine	0.07	2.6
		0.05	5.0
	A survey size a	0.10	1.4
	Asparagine -	0.21	9.7
	Aspertis asid	0.07	1.7
	Aspartic acid	0.21	1.1
	Asymmetric dimethylarginine	0.18	1.5
	Citrulline	0.09	2.1
	Cystine	0.16	7.2
	Dimethylglycine	0.07	5.5
	Clutarria a sid	0.09	1.6
	Glutamic acid	0.27	0.5
		0.10	1.0
	Glutamine	0.06	3.1
		0.08	4.0
	Glycine	0.19	5.9
Amino acid		0.06	4.7
	Histidine	2.12	18.0
	Isoleucine	0.13	1.7
	Leucine	0.10	2.4
		0.08	0.7
	Lysine	0.06	5.0
	Methionine sulfoxide	0.08	2.1
	Ornitine	0.06	2.8
	Phenylalanine	0.07	1.0
		0.14	0.6
	Proline	0.04	2.3
	Serine	0.09	1.9
		0.13	9.3
	Symmetric dimethylarginine	0.22	4.3
		0.09	2.4
	Threonine	0.09	3.5
	Tryptophan	0.04	1.2
		0.13	0.9
	Tyrosine	0.10	2.4
	Valine	0.05	4.8
	Adenine	0.20	2.1
	Adenosine	0.23	9.6
Nucleasider	Adenosine 3',5'-cyclic monophosphate	0.23	14.8
Nucleosides and	Adenosine monophosphate	0.14	3.6
Nucleotides	Cytidine	0.14	1.2
	Cytidine monophosphate	0.23	1.2
	Cytosine	0.07	9.2

Table 1 Detected compounds and their repeatability

Category	Category Compounds		Repeatability (%RSD, n=6)		
		R.T.	Peak area		
	Guanine	0.17	5.8		
Nucleosides and Nucleotides Thym Vucleotides Thym Uracil Uridir Uridir Vidir Xanth Argin Cholio Creat	Guanosine	0.32	2.1		
	Guanosine monophosphate	0.16	6.4		
	Inosine	0.33	1.5		
	Thymidine	0.26	10.1		
	Thymidine monophosphate	0.18	13.1 6.6		
Nucleotides	Thymine	0.05	6.9		
-		0.12	3.1		
		0.07	3.7		
		0.07	8.1		
		0.05	7.6		
		0.06	3.9		
	Guanine Image: state of the	0.06	14.1		
	-	0.14	2.6		
Organic		0.28	2.5		
acid		0.04	5.0		
		0.10	3.4		
		0.16	2.6		
		0.04	4.1		
		0.15	7.0		
	5	0.07	2.9		
TCA cycle		0.14	2.4		
		0.13	6.4		
	Isocitric acid	0.12	5.0		
	Malic acid	0.10	2.8		
	Succinic acid	0.06	2.2		
	Cystathionine	0.14	5.1		
	Cysteine	0.20	7.1		
ranssulfuration	Methionine	0.06	2.5		
	Wethonine	0.04	1.6		
	S-Adenosylhomocysteine	0.12	8.9		
	2-Aminobutyric acid	0.24	4.8		
	6-Phosphogluconic acid	0.04	5.6		
ranssulfuration	Acetylcarnitine	0.15	3.0		
	Allantoin	0.11	4.2		
	Carnitine	0.12	6.9		
	Carnosine	0.16	2.0		
Others	Choline	0.05	1.6		
Others	Creatinine	0.06	3.0		
	Dopamine	0.26	6.4		
	FMN	0.11	8.0		
	Histamine	0.22	2.6		
	Hypoxanthine	0.04	1.4		
	Norepinephrine	0.54	1.7		
	Serotonin	0.06	2.4		

\* Red: the repeatability of compounds using ion-pairing method

Black: the repeatability of compounds using non-ion-pairing method



### Comparison between Young Mice and Old Mice

As an application to fecal metabolomics, feces derived from mice that the age was different (10-week-old and 70-week-old) were analyzed by non-ion-pairing method. As results of analyses for the extracts of the mice feces, 66 of metabolites were detected. By Traverse MS software, principal component analyses (PCA) were performed. As shown in Figure 3, two mice feces were successfully classified. The concentrations of 21 in old mice (70-week-old) feces were obviously lower (p < 0.01) than those in young mice (10-week-old) feces. The lower concentration of fecal cholic acid in old mice feces indicates that the secretion of bile acid was decreased by the ageing. On the other hand, there is a likelihood that the number of bacteria that deconjugate bile acid (taurocholic acid) to taurine and cholic acid, is more in young mice than old mice. In contrast, the concentrations of 26 in old mice feces were obviously higher (p < 0.01) than those in young mice feces. Intestinal luminal arginine is absorbed and converted to polyamines that are essential substances for the proliferation of somatic cells, through ornithine. The lower concentration of arginine in young mice feces indicates that colonocytes of young mice absorb luminal arginine actively to grow compared with old mice. Table 2 shows the list of compounds that showed significant differences between young mice and old mice.




Figure 3 Score plot and loading plot

	Com	pounds		
You	ng mice > Old mice	Old mice > Young mice		
Adenine	Proline	4-Aminobutyric acid	Guanosine monophosphate	
Adenosine	Succinic acid	Adenosine monophosphate	Histamine	
Asparatic acid	Thymidine	Arginine	Histidine	
Carnitine	Thymidine monophosphate	Asymmetric dimethylarginine	Hypoxanthine	
Cholic acid	Thymine	Citrulline	Lactic acid	
Choline	Uracil	Cystine	Lysine	
Cystathionine	Uric acid	Cytidine	Methionine	
Cytosine	Xanthine	Cytidine monophosphate	Methionine sulfoxide	
Fumaric acid		Dimethylglycine	Nicotinic acid	
Glutamic acid		FMN	S-Adenosylmethionine	
Glycine		Glutamine	Serotonin	
Homosysteine		Guanine	Symmetric dimethylarginine	
Isoleucine		Guanosine	Threonine	

Table 2 Compounds that showed significant differences between young mice and old mice

# Conclusions

- We analyzed metabolites in mice fecal by LC-MS/MS (ion-pairing method and non-ion-pairing method) and 17 and 75 of metabolites were detected, respectively.
- As results of analyses by non-ion-paring method and principal component analysis (PCA), two types of mice fecal (young and old) was successfully categorized.
- These analytical methods could be a very powerful tool in fecal metabolomics.

Disclaimer: The products and applications in this presentation are intended for Research Use Only (RUO). Not for use in diagnostic procedures. Not available in China.



Shimadzu Corporation

www.shimadzu.com/an/

#### For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.